Nanomolar-potency ‘co-potentiator’ therapy for cystic fibrosis caused by a defined subset of minimal function CFTR mutants

Available CFTR modulators provide no therapeutic benefit for cystic fibrosis (CF) caused by many loss-of-function mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel, including N1303K. We previously introduced the concept of ‘co-potentiators’ (combination-pot...

Descripción completa

Detalles Bibliográficos
Autores principales: Phuan, Puay-Wah, Tan, Joseph-Anthony, Rivera, Amber A., Zlock, Lorna, Nielson, Dennis W., Finkbeiner, Walter E., Haggie, Peter M., Verkman, Alan S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6881293/
https://www.ncbi.nlm.nih.gov/pubmed/31776420
http://dx.doi.org/10.1038/s41598-019-54158-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6881293/
https://www.ncbi.nlm.nih.gov/pubmed/31776420
http://dx.doi.org/10.1038/s41598-019-54158-2

Ejemplares similares